Biomarkers vs Machines: The Race to Predict Acute Kidney Injury.

Area of Science:

• Nephrology
• Biomarker Discovery
• Artificial Intelligence in Medicine

Background:

• Acute kidney injury (AKI) affects up to 15% of hospitalized patients, often diagnosed late via serum creatinine.
• AKI is clinically silent, necessitating improved early detection to prevent severe morbidity and mortality.

Purpose of the Study:

• To review and critically evaluate recent advancements in AKI detection and prediction.
• To discuss emerging biomarkers and AI tools for AKI diagnosis in adult and pediatric populations.

Main Methods:

• Review of clinical utility studies for novel biomarkers (e.g., cystatin C, NGAL, TIMP-1, IGFBP7).
• Evaluation of machine learning algorithms for AKI detection and prediction.
• Analysis of guidelines and recommendations for clinical practice adoption.

Main Results:

• Emerging biomarkers like cystatin C, NGAL, and the combination of TIMP-1/IGFBP7 show potential for earlier AKI detection.
• Machine learning algorithms demonstrate high accuracy in predicting imminent AKI.
• Regulatory approval for some biomarkers signifies progress in clinical adoption.

Conclusions:

• New biomarkers and AI tools offer significant promise for improving AKI detection and prediction.
• Further clinical outcome studies are essential to validate the real-world utility of these emerging technologies.
• The integration of these tools into clinical practice requires careful consideration and further research.